$0.77
9.27% yesterday
Nasdaq, Dec 03, 10:00 pm CET
ISIN
US0021201035
Symbol
ATYR

aTyr Pharma, Inc. Stock price

$0.77
-0.11 12.48% 1M
-4.62 85.70% 6M
-2.85 78.71% YTD
-2.56 76.85% 1Y
-1.52 66.34% 3Y
-3.77 83.02% 5Y
-122.57 99.38% 10Y
-208.53 99.63% 20Y
Nasdaq, Closing price Wed, Dec 03 2025
+0.07 9.27%
ISIN
US0021201035
Symbol
ATYR
Industry

Key metrics

Basic
Market capitalization
$75.5m
Enterprise Value
$-13.6m
Net debt
positive
Cash
$90.2m
Shares outstanding
98.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
397.5 | 61.7
EV/Sales
negative | negative
EV/FCF
0.2
P/B
0.9
Financial Health
Equity Ratio
72.3%
Return on Equity
-91.4%
ROCE
-86.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$190.0k | $1.2m
EBITDA
$-79.0m | $-72.8m
EBIT
$-78.7m | $-76.2m
Net Income
$-75.1m | $-73.5m
Free Cash Flow
$-63.0m
Growth (TTM | estimate)
Revenue
-20.8% | 410.0%
EBITDA
-19.1% | -8.3%
EBIT
-15.6% | -12.2%
Net Income
-17.7% | -14.8%
Free Cash Flow
6.1%
Margin (TTM | estimate)
Gross
-
EBITDA
-41,571.6% | -5,945.8%
EBIT
-41,395.3%
Net
-39,537.9% | -6,001.9%
Free Cash Flow
-33,154.2%
More
EPS
$-0.8
FCF per Share
$-0.6
Short interest
36.5%
Employees
-
Rev per Employee
-
Show more

Is aTyr Pharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

aTyr Pharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a aTyr Pharma, Inc. forecast:

9x Buy
53%
8x Hold
47%

Analyst Opinions

17 Analysts have issued a aTyr Pharma, Inc. forecast:

Buy
53%
Hold
47%

Financial data from aTyr Pharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
0.19 0.19
21% 21%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 17 17
29% 29%
9,100%
- Research and Development Expense 62 62
12% 12%
32,400%
-79 -79
19% 19%
-41,574%
- Depreciation and Amortization -0.34 -0.34
120% 120%
-179%
EBIT (Operating Income) EBIT -79 -79
16% 16%
-41,395%
Net Profit -75 -75
18% 18%
-39,537%

In millions USD.

Don't miss a Thing! We will send you all news about aTyr Pharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

aTyr Pharma, Inc. Stock News

Neutral
GlobeNewsWire
about 12 hours ago
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of aTyr Pharma, Inc. (NASDAQ: ATYR).
Neutral
GlobeNewsWire
about 19 hours ago
Faruqi & Faruqi, LLP Securities Litigation Partner  James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options
Neutral
PRNewsWire
one day ago
NEW YORK , Dec. 2, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of aTyr Pharma, Inc. (NASDAQ: ATYR) between January 16, 2025 and September 12, 2025, both dates inclusive (the "Class Period"), of the important December 8, 2025 lead plaintiff deadline. So what: If you purchased aTyr Pharma common stock during the Class Period you ...
More aTyr Pharma, Inc. News

Company Profile

aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. It operates in a single accounting segment. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Head office United States
CEO Sanjay Shukla
Founded 2005
Website www.atyrpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today